03:08 , Sep 23, 2017 |  BioCentury  |  Emerging Company Profile

Selective suppression

Kezar Life Sciences Inc. is targeting the immunoproteasome to selectively suppress the hyperactive immune cells that drive autoimmunity. The company expects its biologics to have the rapid onset and broad activity of steroids, but without...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Financial News

Kezar Life Sciences completes venture financing

Kezar Life Sciences Inc., South San Francisco, Calif.   Business: Autoimmune   Date completed: 2015-06-16   Type: Venture financing   Raised: $23 million   Investors: Morningside Venture Investments; Cormorant Asset Management; EcoR1 Capital; 9W Capital Management; Omega Funds; AJU IB...
01:01 , Jun 17, 2015 |  BC Extra  |  Financial News

Onyx spinout Kezar raises $23M in series A

Kezar Life Sciences Inc. (South San Francisco, Calif.), a newco that houses assets spun out from the Onyx Pharmaceuticals Inc. subsidiary of Amgen Inc. (NASDAQ:AMGN), raised $23 million in a series A round. Investors included...